Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Quantum Pharma's Colonis Gets Approval For Ergocalciferol Launch

19th Apr 2016 08:50

LONDON (Alliance News) - Niche pharmaceuticals company Quantum Pharma PLC on Tuesday said its Colonis Pharma Ltd unit has secured approval to launch Ergocalciferol 50,000 IU capsules in the UK, part of the Quantum vitamin D portfolio.

Ergocalciferol is a form of vitamin D that is produced from natural non-animal sources and is used to prevent and treat vitamin D deficiency.

"We are pleased to announce the upcoming launch of Ergocalciferol 50,000 IU capsules which represents the first licensed presentation of this product in the UK. This marks further progress in our strategy to deliver unlicensed to licensed and other niche products to the market," said Andrew Scaife, Quantum's chief executive.

Quantum shares were up 2.3% to 64.46 pence.

By Sam Unsted; [email protected]; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.


Related Shares:

Quantum Pharma
FTSE 100 Latest
Value8,809.74
Change53.53